文献速递头颈甲状腺与浅表技术与安全US

甲状腺乳头状癌隐匿性V区淋巴结转移的术前预测:放射组学驱动列线图模型的开发与验证

Preoperative Prediction of Occult Level V Lymph Node Metastasis in Papillary Thyroid Carcinoma: Development and Validation of a Radiomics-Driven Nomogram Model.
PubMed 文献 · Acad Radiol · 2024-10-22

回顾性分析325例接受甲状腺切除术及治疗性颈侧区淋巴结清扫的甲状腺乳头状癌患者,按70%与30%随机分为训练集与验证集,基于超声图像构建放射组学特征模型并与临床特征模型比较。放射组学模型预测V区淋巴结转移的AUC在训练集为0.933、验证集为0.912,优于临床特征模型(训练集AUC 0.749),并以列线图形式呈现。

要点

  • 放射组学列线图预测V区淋巴结转移训练集AUC 0.933、验证集AUC 0.912。
  • 临床特征模型由肿瘤边缘、同时性转移和高负荷侧区淋巴结转移构成,训练集AUC 0.749。
  • 放射组学模型在敏感度、特异度、阳性预测值、阴性预测值上均优于临床模型。

核心结论

  • 放射组学特征模型在预测甲状腺乳头状癌患者V区淋巴结转移方面优于临床特征模型,以列线图形式为术前评估提供工具,可能有助于优化临床决策和个体化治疗策略。

研究设计与样本

  • 回顾性分析2020年10月至2023年1月325例接受甲状腺切除术及治疗性单侧或双侧颈侧区改良根治性淋巴结清扫的甲状腺乳头状癌患者,随机按70%与30%分为训练集与验证集;基于超声图像使用最小冗余最大相关性和最小绝对收缩与选择算子回归提取高通量定量特征构建放射组学特征模型;基于与V区淋巴结转移相关的显著临床因素构建临床特征模型并各自转换为列线图。

诊断标准与关键数值

  • 放射组学特征模型(未纳入临床因素)训练集AUC 0.933,验证集AUC 0.912。
  • 临床特征模型(由肿瘤边缘、同时性转移、高负荷侧区淋巴结转移构成)训练集AUC 0.749。
  • 放射组学特征模型在两个队列中的敏感度、特异度、阳性预测值、阴性预测值均表现更优。
  • 决策曲线分析显示放射组学特征模型具有临床实用性。

临床应用与阅片要点

  • 作者认为放射组学列线图可作为术前评估工具,可能有助于优化临床决策和个体化治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: The study aimed to analyze the patterns and frequency of Level V lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC), identify its risk factors, and construct predictive models for assessment.

METHODS: We conducted a retrospective analysis of 325 PTC patients who underwent thyroidectomy and therapeutic unilateral bilateral modified radical neck dissection from October 2020 to January 2023. Patients were randomly allocated into a training cohort (70%) and a validation cohort (30%). The radiomics signature model was developed using ultrasound images, applying the minimum Redundancy-Maximum Relevance and Least Absolute Shrinkage and Selection Operator regression to extract high-throughput quantitative features. Concurrently, the clinic signature model was formulated based on significant clinical factors associated with Level V LNM. Both models were independently translated into nomograms for ease of clinical use.

RESULTS: The radiomics signature model, without the inclusion of clinical factors, showed high discriminative power with an area under the curve (AUC) of 0.933 in the training cohort and 0.912 in the validation cohort. Conversely, the clinic signature model, composed of tumor margin, simultaneous metastasis, and high-volume lateral LNM, achieved an AUC of 0.749 in the training cohort. The radiomics signature model exhibited superior performance in sensitivity, specificity, positive predictive value, negative predictive value across both cohorts. Decision curve analysis demonstrated the clinical utility of the radiomics signature model, indicating its potential to guide more precise treatment decisions.

CONCLUSION: The radiomics signature model outperformed the clinic signature model in predicting Level V LNM in PTC patients. The radiomics signature model, available as a nomogram, offers a promising tool for preoperative assessment, with the potential to refine clinical decision-making and individualize treatment strategies for PTC patients with potential Level V LNM.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Feng JW, Zheng F, Liu SQ, et al. Preoperative Prediction of Occult Level V Lymph Node Metastasis in Papillary Thyroid Carcinoma: Development and Validation of a Radiomics-Driven Nomogram Model. Acad Radiol. 2024. PMID: 39443241. doi:10.1016/j.acra.2024.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。